Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience Corporation (TWST) reported that Anthropic, PBC published a blog post describing results from a multi-arm protein design campaign against 15 targets using its Claude Opus 4.8 and Mythos Preview AI models. Anthropic selected Twist Bioscience as one of its independent evaluators to rapidly manufacture these AI-designed proteins at scale and test them for binding.
The disclosure is made under Regulation FD and is furnished, not filed, meaning it is not automatically incorporated into Twist Bioscience’s Securities Act filings unless specifically referenced there.
Twist Bioscience Corp (TWST) received a Rule 144 notice for a potential resale of up to 78,355 shares of common stock by officer Patrick Finn through Fidelity Brokerage Services LLC. The shares have an indicated aggregate market value of $9,528,751.55. Twist Bioscience reports 62,707,424 shares outstanding as of August 18, 2026; this is a baseline figure, not the amount being sold. The shares to be sold were acquired mainly via restricted stock vesting and a 23,355-share stock option exercise on August 18, 2026, and follow prior sales in the last three months.
Twist Bioscience Corp director Katryn Blake reported a sale of 2,240 shares of common stock on August 12, 2026 at $122.88 per share. According to the company’s disclosure, the shares were sold to cover tax liabilities arising from the vesting of Restricted Stock Units pursuant to a prior election and did not represent a discretionary trade. Following this transaction, Blake directly holds 17,208 shares of Twist Bioscience common stock.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an option exercise and share sale on August 12, 2026. She exercised 19,952 Employee Stock Options at an exercise price of $26.66 per share, receiving an equal number of common shares. The same day, she sold 19,952 common shares at a weighted average price of $125.0756 per share in transactions executed under a previously adopted Rule 10b5-1 trading plan.
The option exercised relates to a grant expiring on November 18, 2028. Additional stock option holdings are reported with exercise prices of $5.95, $8.82, $23.33, and $67.85, with expirations between 2025 and 2030, showing remaining equity-based incentives.
ARK Investment Management LLC and its founder Catherine D. Wood report beneficial ownership of 4,549,803 shares of Twist Bioscience Corp common stock, representing 7.31% of the class.
ARK has sole voting power over 4,254,988 shares and shared voting power over 58,669 shares. It also has sole dispositive power over 4,549,803 shares. Catherine D. Wood has shared voting power over 4,313,657 shares and shared dispositive power over 4,549,803 shares, with no sole voting or dispositive power.
T. Rowe Price Associates, Inc. reported beneficial ownership of 3,634,470 shares of Twist Bioscience Corp.5.8% of the company’s common stock. T. Rowe Price Associates reported sole voting power over 3,520,536 shares and sole dispositive power over 3,634,470 shares, with no shared voting or dispositive power. The firm is organized in Maryland and states that this filing should not be construed as an admission that it is the beneficial owner of the referenced securities, and such beneficial ownership is expressly denied.
EdgePoint Investment Group Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Twist Bioscience Corp. EdgePoint reports beneficial ownership of 2,521,635 shares, representing 4.21% of the outstanding common stock as of June 30, 2026.
EdgePoint reports 1,945,483 shares with sole voting and dispositive power and 576,152 shares with shared voting and dispositive power. The filing notes that EdgePoint acts as investment manager for multiple private investment funds and mutual fund trusts that directly own the shares and that its holdings represent ownership of 5 percent or less of the class.
Artisan Partners Asset Management Inc., together with affiliated entities, reports beneficial ownership of 4,802,017 common shares of Twist Bioscience Corporation. This represents 7.7% of the common shares outstanding, based on 62,271,314 shares outstanding as of April 29, 2026.
The group reports shared voting power over 4,215,805 shares and shared dispositive power over all 4,802,017 shares, with no sole voting or dispositive power. The shares are held on behalf of discretionary clients of Artisan Partners Limited Partnership, which is a registered investment adviser; those clients receive all dividends and sale proceeds, and none is known to hold more than 5% of the class.
Twist Bioscience insider Emily M. Leproust filed to resell up to 19,952 shares of common stock, held at Fidelity Brokerage Services, with an aggregate market value of $2,495,507.42, in a transaction related to a stock option exercise dated August 12, 2026, on NASDAQ. The filing also lists prior common stock sales over the past three months, including 113,318 shares for $14,183,062.19 on August 10, 2026. The issuer reports 62,707,424 shares of common stock outstanding as a baseline figure.
Twist Bioscience Corp CEO Emily M. Leproust reported an option exercise and share sale under a previously adopted Rule 10b5-1 trading plan. She exercised 113,318 stock options at $26.66 per share into common stock and on the same date sold 113,318 shares at a weighted average price of $125.1615 per share, with individual sale prices ranging from $125.00 to $125.51. The filing also lists several remaining employee stock option awards with exercise prices between $5.95 and $67.85 and expiration dates from 2025 to 2030.